Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China

Journal of Digestive Diseases

Volumn 9, Issue 2, 2008, Pages 84-88

  Zheng, Jia Ju ^a   Chu, Xing Qi ^a   Shi, Xiao Hua ^a   Zhou, Chun Li ^a   Seng, Bi Wu ^a  

^a SUZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

Azathioprine; C reactive protein; Crohn's disease; Crohn's Disease Activity Index; Erythrocytesedimentation rate; Harvey Bradshaw index

Indexed keywords

AZATHIOPRINE; LEUCOGENENOL; MESALAZINE; PREDNISONE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CHINA; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTESTINE RESECTION; LEUKOPENIA; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CHINA; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 42449099389     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2008.00327.x     Document Type: Article

References (14)

1. Lémann M, Mary JY, Colombel JF et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-18.
2. Candy S, Wright JP, Gerber M et al. A controlled double blind study of azathioprine in the treatment and maintenance of CD. Gut 1995; 37: 674-8.
3. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30.year review. Gut 2002; 50: 485-9.
4. Pearson DC, May GR, Fick GH et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123: 132-4.
5. Cosnes J, Nion-Larmurier I, Beaugerie L et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41.
6. Chinese Medical Association (Branch of Digestive Disease). A consensus for the diagnosis and treatment of inflammatory bowel disease. Chin J Dig Dis 2001; 21: 236-9 (in Chinese).
7. Zheng JJ, Zhu XS, Huangfu Z et al. Crohn's disease in mainland China: A systemic analysis of 50.years of research. Chin J Dig Dis 2005; 6: 175-81.
8. Best WR, Becktel JM, Singletion JW et al. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976; 70: 439-44.
9. Hanauer SB, Korelitz BI, Rutgeerts P et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial. Gastroenterology 2004; 127: 723-9.
10. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514.
11. Satsangi J, Silverberg MS, Vermiere S et al. The Montreal classification of inflammatory bowel disease. Controversies, consensus, implications. Gut 2006; 55: 749-53.
12. Zheng JJ. The pharmacology and clinical use of purine analogues in inflammatory bowel disease. Chin J Gastroenterol 2003; 8: 253-5 (in Chinese).
13. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin N Am 2004; 33: 209-34.
14. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996; 91: 423-33.